John M Luk

Summary

Affiliation: National University of Singapore
Country: Singapore

Publications

  1. pmc microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma
    Julja Burchard
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, WA, USA
    Mol Syst Biol 6:402. 2010
  2. pmc A protein-based set of reference markers for liver tissues and hepatocellular carcinoma
    Stella Sun
    Department of Surgery, LKS Faculty of Medicine, Jockey Club Clinical Research Centre, The University of Hong Kong, Pokfulam, Hong Kong
    BMC Cancer 9:309. 2009
  3. pmc Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
    Lei Chen
    Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Ann Surg Oncol 17:2518-25. 2010
  4. doi Proteomics of hepatocellular carcinoma in Chinese patients
    John M Luk
    Department of Pharmacology, Cancer Science Institute, National University of Singapore, Singapore
    OMICS 15:261-6. 2011
  5. pmc DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival
    John M Luk
    Cancer Science Institute and Department of Pharmacology, National University of Singapore, 117597, Singapore
    J Biol Chem 286:30706-13. 2011
  6. doi Global regulation on microRNA in hepatitis B virus-associated hepatocellular carcinoma
    Angela M Liu
    Department of Pharmacology, Cancer Science Institute, National University of Singapore, Singapore
    OMICS 15:187-91. 2011
  7. pmc miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma
    Angela M Liu
    Department of Pharmacology, National University of Singapore, Singapore Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    PLoS ONE 9:e86872. 2014
  8. pmc Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma
    Irena Ivanovska
    Rosetta Inpharmatics LLC, Merck and Co, Inc, Seattle, Washington, United States of America
    PLoS ONE 6:e24582. 2011
  9. doi Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma
    Kwong Fai Wong
    Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
    Methods Mol Biol 909:295-310. 2012
  10. doi Circulating markers for prognosis of hepatocellular carcinoma
    Kwong Fai Wong
    National University Health System, Department of Pharmacology, Singapore
    Expert Opin Med Diagn 7:319-29. 2013

Collaborators

  • Nikki P Lee
  • Feng Li
  • Gautam Sethi
  • Peramaiyan Rajendran
  • Irena Ivanovska
  • Wei Wang
  • Guo Hao Wu
  • Daniel G Tenen
  • Ke Hao
  • John R Lamb
  • Kwong Fai Wong
  • Angela M Liu
  • Ronnie T Poon
  • Zhi Xu
  • Jinfei Chen
  • Julja Burchard
  • Stella Sun
  • Dong xing Cao
  • Hongyue Dai
  • Chunsheng Zhang
  • Lei Chen
  • Ronnie T P Poon
  • Xin Yi
  • Felix H Shek
  • Yick Liang Lum
  • Yiting Qiao
  • Yi Yuan
  • Xiao Ou Jiang
  • Zhi Jie Li
  • Xiaoou Jiang
  • Ester Khin
  • S T Fan
  • Michelle Z Xu
  • George Tokiwa
  • Brendan Leeson
  • Rebecca Beard
  • Zongwei Cai
  • Mark D Ferguson
  • Terence C W Poon
  • Lee Lim
  • Jana Wo
  • Mao Mao
  • David Ho
  • Jirun Peng
  • Eddy W Y Ng
  • Paul B S Lai
  • Brian Y Lam
  • Ryan Smith
  • David W Y Ho
  • Pak C Sham
  • George K Lau
  • Xisheng Leng
  • Brian Lam
  • Jose M Casasnovas
  • Chun Yeung
  • Philip J R Day
  • Ronnie Tp Poon

Detail Information

Publications19

  1. pmc microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma
    Julja Burchard
    Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, WA, USA
    Mol Syst Biol 6:402. 2010
    ..In conclusion, miR-122 regulates mitochondrial metabolism and its loss may be detrimental to sustaining critical liver function and contribute to morbidity and mortality of liver cancer patients...
  2. pmc A protein-based set of reference markers for liver tissues and hepatocellular carcinoma
    Stella Sun
    Department of Surgery, LKS Faculty of Medicine, Jockey Club Clinical Research Centre, The University of Hong Kong, Pokfulam, Hong Kong
    BMC Cancer 9:309. 2009
    ..This is the first study employed 2-DE analysis to screen for potential reference markers and aims to correlate the abundance of these proteins with their level of transcript expression...
  3. pmc Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
    Lei Chen
    Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Ann Surg Oncol 17:2518-25. 2010
    ..We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis...
  4. doi Proteomics of hepatocellular carcinoma in Chinese patients
    John M Luk
    Department of Pharmacology, Cancer Science Institute, National University of Singapore, Singapore
    OMICS 15:261-6. 2011
    ....
  5. pmc DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival
    John M Luk
    Cancer Science Institute and Department of Pharmacology, National University of Singapore, 117597, Singapore
    J Biol Chem 286:30706-13. 2011
    ..In conclusion, our findings suggest that coordinate up-regulation of the DLK1-DIO3 miRNA cluster at 14q32.2 may define a novel molecular (stem cell-like) subtype of HCC associated with poor prognosis...
  6. doi Global regulation on microRNA in hepatitis B virus-associated hepatocellular carcinoma
    Angela M Liu
    Department of Pharmacology, Cancer Science Institute, National University of Singapore, Singapore
    OMICS 15:187-91. 2011
    ..This study provides molecular clues that may contribute to the global changes of miRNA expression in HCC...
  7. pmc miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma
    Angela M Liu
    Department of Pharmacology, National University of Singapore, Singapore Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    PLoS ONE 9:e86872. 2014
    ..The present study demonstrated the regulatory role of miR-122 on PKM2 in HCC, having an implication of therapeutic intervention targeting cancer metabolic pathways. ..
  8. pmc Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma
    Irena Ivanovska
    Rosetta Inpharmatics LLC, Merck and Co, Inc, Seattle, Washington, United States of America
    PLoS ONE 6:e24582. 2011
    ....
  9. doi Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma
    Kwong Fai Wong
    Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
    Methods Mol Biol 909:295-310. 2012
    ..Focus is emphasized on the methods for sample preservation and low-abundance protein enrichment...
  10. doi Circulating markers for prognosis of hepatocellular carcinoma
    Kwong Fai Wong
    National University Health System, Department of Pharmacology, Singapore
    Expert Opin Med Diagn 7:319-29. 2013
    ..As such, it remains imperative to develop accurate, noninvasive blood tests, which can be applied in most clinical laboratories, for the measurement of treatment responses and the surveillance for tumor recurrence...
  11. pmc Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
    Gautam Sethi
    Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
    Mol Cancer 13:66. 2014
    ..Here we report, garcinol, a polyisoprenylated benzophenone, could suppress STAT3 activation in HCC cell lines and in xenografted tumor of HCC in nude mice model...
  12. pmc Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters
    Ke Hao
    1Rosetta Inpharmatics LLC, Merck Research Laboratories, Seattle, WA, USA
    BMC Cancer 9:389. 2009
    ..However, the results are not consistent due to lack of systemic approach to establish a prediction model incorporating all these parameters...
  13. doi Targeting YAP and Hippo signaling pathway in liver cancer
    Angela M Liu
    Department of Pharmacology, National University of Singapore, 117597, Singapore
    Expert Opin Ther Targets 14:855-68. 2010
    ..Recently, YAP has been implicated as a bona fide oncogene in solid tumors, but little is known about its exact molecular mechanism in carcinogenesis...
  14. doi Regulators of mammalian Hippo pathway in cancer
    Angela M Liu
    Department of Pharmacology, National University of Singapore, Singapore
    Biochim Biophys Acta 1826:357-64. 2012
    ..Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments...
  15. pmc Prophylactic uses of integrin CD18-betaA peptide in a murine polymicrobial peritonitis model
    Kwong Fai Wong
    Department of Pharmacology and Surgery, National University Hospital System, National University of Singapore, Singapore 117597, Singapore
    World J Gastroenterol 16:2648-56. 2010
    ..To evaluate the prophylactic properties of integrin CD18-betaA peptide in a murine model of abdominal polymicrobial peritonitis and sepsis...
  16. pmc Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers
    Dong xing Cao
    Dong Xing Cao, Zhi Jie Li, Xiao Ou Jiang, Yick Liang Lum, Ester Khin, John M Luk, Department of Pharmacology and Department of Surgery, National University Health System, National University of Singapore, Singapore 117597, Singapore
    World J Gastroenterol 18:3923-30. 2012
    ..Better understanding of the implications of OPN in tumorigenesis might facilitate development of therapeutic regimens to benefit patients with these deadly malignancies...
  17. doi Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo
    Peramaiyan Rajendran
    Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
    Cancer Prev Res (Phila) 5:631-43. 2012
    ..Overall, our results suggest for the first time that celastrol exerts its antiproliferative and proapoptotic effects through suppression of STAT3 signaling in HCC both in vitro and in vivo...
  18. doi An update on targeting Hippo-YAP signaling in liver cancer
    Angela M Liu
    Department of Oncology, Nanjing Medical University, Nanjing, China
    Expert Opin Ther Targets 16:243-7. 2012
    ..This knowledge provides a basis for rational design of therapeutics against cancer that depends upon Hippo-YAP signaling for growth...
  19. doi Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents
    Kwong Fai Wong
    Cancer Science Institute of SingaporeDepartments of PharmacologySurgery, National University Health System, National University of Singapore, Singapore
    Clin Exp Pharmacol Physiol 39:311-20. 2012
    ..5. Triptolide derivatives with improved water solubility have emerged as promising drug candidates. Clinical trials are being conducted on the derivatives to provide encyclopaedic knowledge on triptolide pharmacokinetics in patients...